Coleman Research Group’s Healthcare Team facilitates consultations between our clients (institutional investors) and leading healthcare professionals on a wide variety of topics including pharmaceuticals, biotechnology, clinical research, medical devices, healthcare providers, insurance, and regulatory issues.
Our Healthcare network spans technology industries across the globe and includes doctors, researchers, scientists, healthcare executives, consultants, and former regulatory officials.
********************************
Silver Nanoparticles Show 'Immense Potential' In Prevention Of Blood Clots
June 2, 2009
Scientists are reporting discovery of a potential new alternative to aspirin, ReoPro, and other anti-platelet agents used widely to prevent blood clots in coronary artery disease, heart attack and stroke. Their study involves particles of silver — 1/50,000th the diameter of a human hair — that are injected into the bloodstream.
Debabrata Dash and colleagues point out that patients urgently need new anti-thrombotic agents because traditionally prescribed medications too-often cause dangerous bleeding. At the same time, aging of the population, sedentary lifestyle and spiraling rates of certain diseases have increased the use of these drugs. Researchers are seeking treatments that more gently orchestrate activity of platelets, disk-shaped particles in the blood that form clots.
********************************
Citalopram No Better Than Placebo Treatment For Children With Autism Spectrum Disorders
June 2, 2009
Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.
"Parents of children with autism spectrum disorders face an enormous number of treatment options, not all of which are research-based," said NIMH Director Thomas R. Insel, M.D. "Studies like this help us to better understand which treatments are likely to be beneficial and safe."
The researchers say their findings do not support using citalopram to treat repetitive behaviors in children with ASD. Also, the greater frequency of side effects from this particular medication compared to placebo illustrates the importance of placebo-controlled trials in evaluating medications currently prescribed to this population.
********************************
To learn more about Coleman Research Group please visit the Coleman Research Group website or at any of the links below:
About Coleman Research Group
Coleman Research Group Testimonials
Coleman Research Group on LinkedIn
Coleman Research Group on Facebook
Coleman Research Group on Flickr
Coleman Research Group on Squidoo
Coleman Research Group on Namyz
Coleman Research Group on Twitter
Coleman Research Group on Review-Inc
Coleman Research Group Contact Us
Coleman Research Group on 800 Review
Coleman Research Group on Blogspot
Coleman Research Group on Jobster
Coleman Research Group's Knowledge Broker
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment